|
1
|
Wong MCS, Hamilton W, Whiteman DC, Jiang
JY, Qiao Y, Fung FD, Wang HH, Chiu PW, Ng EK, Wu JC, et al: Global
incidence and mortality of oesophageal cancer and their correlation
with socioeconomic indicators temporal patterns and trends in 41
countries. Sci Rep. 8:45222018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hurwitz M: Chemotherapy in prostate
cancer. Curr Oncol Rep. 17:442015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
McGrogan BT, Gilmartin B, Carney DN and
McCann A: Taxanes, microtubules and chemoresistant breast cancer.
Biochim Biophys Acta. 1785:96–132. 2008.
|
|
4
|
Zhu ML, Horbinski CM, Garzotto M, Qian DZ,
Beer TM and Kyprianou N: Tubulin-targeting chemotherapy impairs
androgen receptor activity in prostate cancer. Cancer Res.
70:7992–8002. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Darshan MS, Loftus MS, Thadani-Mulero M,
Levy BP, Escuin D, Zhou XK, Gjyrezi A, Chanel-Vos C, Shen R, Tagawa
ST, et al: Taxane-induced blockade to nuclear accumulation of the
androgen receptor predicts clinical responses in metastatic
prostate cancer. Cancer Res. 71:6019–6029. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hotte SJ: Addressing taxane resistance in
metastatic castration-resistant prostate cancer: A focus on
chaperone proteins. Future Oncol. 13:369–379. 2017. View Article : Google Scholar
|
|
7
|
Magadoux L, Isambert N, Plenchette S,
Jeannin JF and Laurens V: Emerging targets to monitor and overcome
docetaxel resistance in castration resistant prostate cancer
(Review). Int J Oncol. 45:919–928. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Galletti G, Leach BI, Lam L and Tagawa ST:
Mechanisms of resistance to systemic therapy in metastatic
castration-resistant prostate cancer. Cancer Treat Rev. 57:16–27.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yao YS, Qiu WS, Yao RY, Zhang Q, Zhuang
LK, Zhou F, Sun LB and Yue L: miR-141 confers docetaxel
chemoresistance of breast cancer cells via regulation of EIF4E
expression. Oncol Rep. 33:2504–2512. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zu S, Ma W, Xiao P, Cui Y, Ma T, Zhou C
and Zhang H: Evaluation of docetaxel-sensitive and
docetaxel-resistant proteomes in PC-3 cells. Urol Int. 95:114–119.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Miyake H, Muramaki M, Furukawa J,
Kurahashi T and Fujisawa M: Serum level of clusterin and its
density in men with prostate cancer as novel biomarkers reflecting
disease extension. Urology. 75:454–459. 2010. View Article : Google Scholar
|
|
12
|
Zoubeidi A, Chi K and Gleave M: Targeting
the cytoprotective chaperone, clusterin, for treatment of advanced
cancer. Clin Cancer Res. 16:1088–1093. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Trougakos IP, Djeu JY, Gonos ES and
Boothman DA: Advances and challenges in basic and translational
research on clusterin. Cancer Res. 69:403–406. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rohne P, Prochnow H, Wolf S, Renner B and
Koch-Brandt C: The chaperone activity of clusterin is dependent on
glycosylation and redox environment. Cell Physiol Biochem.
34:1626–1639. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhong B, Sallman DA, Gilvary DL, Pernazza
D, Sahakian E, Fritz D, Cheng JQ, Trougakos I, Wei S and Djeu JY:
Induction of clusterin by AKT - role in cytoprotection against
docetaxel in prostate tumor cells. Mol Cancer Ther. 9:1831–1841.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhou J, Chen X, Gilvary DL, Tejera MM,
Eksioglu EA, Wei S and Djeu JY: HMGB1 induction of clusterin
creates a chemoresistant niche in human prostate tumor cells. Sci
Rep. 5:150852015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Muhammad LA and Saad F: The role of
clusterin in prostate cancer: Treatment resistance and potential as
a therapeutic target. Expert Rev Anticancer Ther. 15:1049–1061.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tellez T, Garcia-Aranda M and Redondo M:
The role of clusterin in carcinogenesis and its potential utility
as therapeutic target. Curr Med Chem. 23:4297–4308. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lamoureux F, Thomas C, Yin MJ, Kuruma H,
Beraldi E, Fazli L, Zoubeidi A and Gleave ME: Clusterin inhibition
using OGX-011 synergistically enhances Hsp90 inhibitor activity by
suppressing the heat shock response in castrate-resistant prostate
cancer. Cancer Res. 71:5838–5849. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Higano CS: Potential use of custirsen to
treat prostate cancer. OncoTargets Ther. 6:785–797. 2013.
View Article : Google Scholar
|
|
21
|
Chi KN, Hotte SJ, Yu EY, Tu D, Eigl BJ,
Tannock I, Saad F, North S, Powers J, Gleave ME, et al: Randomized
phase II study of docetaxel and prednisone with or without OGX-011
in patients with metastatic castration-resistant prostate cancer. J
Clin Oncol. 28:4247–4254. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Saad F, Hotte S, North S, Eigl B, Chi K,
Czaykowski P, Wood L, Pollak M, Berry S, Lattouf JB, et al Canadian
Uro-Oncology Group: Randomized phase II trial of Custirsen
(OGX-011) in combination with docetaxel or mitoxantrone as
second-line therapy in patients with metastatic castrate-resistant
prostate cancer progressing after first-line docetaxel: CUOG trial
P-06c. Clin Cancer Res. 17:5765–5773. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Blumenstein B, Saad F, Hotte S, Chi KN,
Eigl B, Gleave M and Jacobs C: Reduction in serum clusterin is a
potential therapeutic biomarker in patients with
castration-resistant prostate cancer treated with custirsen. Cancer
Med. 2:468–477. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Moretti RM, Mai S, Montagnani Marelli M,
Rizzi F, Bettuzzi S and Limonta P: Molecular mechanisms of the
antimetastatic activity of nuclear clusterin in prostate cancer
cells. Int J Oncol. 39:225–234. 2011.PubMed/NCBI
|
|
25
|
Scaltriti M, Santamaria A, Paciucci R and
Bettuzzi S: Intracellular clusterin induces G2-M phase arrest and
cell death in PC-3 prostate cancer cells. Cancer Res. 64:6174–6182.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Prochnow H, Gollan R, Rohne P, Hassemer M,
Koch-Brandt C and Baiersdörfer M: Non-secreted clusterin isoforms
are translated in rare amounts from distinct human mRNA variants
and do not affect Bax-mediated apoptosis or the NF-κB signaling
pathway. PLoS One. 8:e753032013. View Article : Google Scholar
|
|
27
|
Huang CY, Beer TM, Higano CS, True LD,
Vessella R, Lange PH, Garzotto M and Nelson PS: Molecular
alterations in prostate carcinomas that associate with in vivo
exposure to chemotherapy: Identification of a cytoprotective
mechanism involving growth differentiation factor 15. Clin Cancer
Res. 13:5825–5833. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhao L, Lee BY, Brown DA, Molloy MP, Marx
GM, Pavlakis N, Boyer MJ, Stockler MR, Kaplan W, Breit SN, et al:
Identification of candidate biomarkers of therapeutic response to
docetaxel by proteomic profiling. Cancer Res. 69:7696–7703. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shim M and Eling TE: Protein kinase
C-dependent regulation of NAG-1/placental bone morphogenic
protein/MIC-1 expression in LNCaP prostate carcinoma cells. J Biol
Chem. 280:18636–18642. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Patel SA and Hoffman-Censits J:
Cabazitaxel in the treatment of metastatic castration-resistant
prostate cancer: Patient selection and special considerations.
OncoTargets Ther. 10:4089–4098. 2017. View Article : Google Scholar
|
|
31
|
Frederiksen LJ, Sullivan R, Maxwell LR,
Macdonald-Goodfellow SK, Adams MA, Bennett BM, Siemens DR and
Graham CH: Chemosensitization of cancer in vitro and in vivo by
nitric oxide signaling. Clin Cancer Res. 13:2199–2206. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Huerta-Yepez S, Baritaki S, Baay-Guzman G,
Hernandez-Luna MA, Hernandez-Cueto A, Vega MI and Bonavida B:
Contribution of either YY1 or BclXL-induced inhibition by the
NO-donor DETANONOate in the reversal of drug resistance, both in
vitro and in vivo. YY1 and BclXL are overexpressed in prostate
cancer. Nitric Oxide. 29:17–24. 2013. View Article : Google Scholar
|
|
33
|
Huerta S, Baay-Guzman G, Gonzalez-Bonilla
CR, Livingston EH, Huerta-Yepez S and Bonavida B: In vitro and in
vivo sensitization of SW620 metastatic colon cancer cells to
CDDP-induced apoptosis by the nitric oxide donor DETANONOate:
Involvement of AIF. Nitric Oxide. 20:182–194. 2009. View Article : Google Scholar
|
|
34
|
Gao X, Saha D, Kapur P, Anthony T,
Livingston EH and Huerta S: Radiosensitization of HT-29 cells and
xenografts by the nitric oxide donor DETANONOate. J Surg Oncol.
100:149–158. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kaliyaperumal K, Sharma AK, McDonald DG,
Dhindsa JS, Yount C, Singh AK, Won JS and Singh I:
S-Nitrosoglutathione-mediated STAT3 regulation in efficacy of
radiotherapy and cisplatin therapy in head and neck squamous cell
carcinoma. Redox Biol. 6:41–50. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Selvendiran K, Bratasz A, Tong L, Ignarro
LJ and Kuppusamy P: NCX-4016, a nitro-derivative of aspirin,
inhibits EGFR and STAT3 signaling and modulates Bcl-2 proteins in
cisplatin-resistant human ovarian cancer cells and xenografts. Cell
Cycle. 7:81–88. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Huerta-Yepez S, Vega M, Escoto-Chavez SE,
Murdock B, Sakai T, Baritaki S and Bonavida B: Nitric oxide
sensitizes tumor cells to TRAIL-induced apoptosis via inhibition of
the DR5 transcription repressor Yin Yang 1. Nitric Oxide. 20:39–52.
2009. View Article : Google Scholar
|
|
38
|
Bonavida B and Baritaki S: Inhibition of
epithelial-to-mesen-chymal transition (EMT) in cancer by nitric
oxide: Pivotal roles of nitrosylation of NF-κB, YY1 and Snail. For
Immunopathol Dis Therap. 3:125–133. 2012. View Article : Google Scholar
|
|
39
|
Baritaki S, Huerta-Yepez S, Sahakyan A,
Karagiannides I, Bakirtzi K, Jazirehi A and Bonavida B: Mechanisms
of nitric oxide-mediated inhibition of EMT in cancer: Inhibition of
the metastasis-inducer Snail and induction of the
metastasis-suppressor RKIP. Cell Cycle. 9:4931–4940. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Girard FP, Byrne J, Downes M, Fanning D,
Desgrandchamps F, Fitzpatrick JM and Watson RW: Detecting soluble
clusterin in in-vitro and in-vivo models of prostate cancer.
Neoplasma. 57:488–493. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yousfi N, Pruvot B, Lopez T, Magadoux L,
Franche N, Pichon L, Salvadori F, Solary E, Garrido C, Laurens V,
et al: The impact of tumor nitric oxide production on VEGFA
expression and tumor growth in a zebrafish rat glioma xenograft
model. PLoS One. 10:e01204352015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Xu W, Foster BA, Richards M, Bondioli KR,
Shah G and Green CC: Characterization of prostate cancer cell
progression in zebrafish xenograft model. Int J Oncol. 52:252–260.
2018.
|
|
43
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
44
|
Shiota M, Zardan A, Takeuchi A, Kumano M,
Beraldi E, Naito S, Zoubeidi A and Gleave ME: Clusterin mediates
TGF-β-induced epithelial-mesenchymal transition and metastasis via
Twist1 in prostate cancer cells. Cancer Res. 72:5261–5272. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lourda M, Trougakos IP and Gonos ES:
Development of resistance to chemotherapeutic drugs in human
osteosarcoma cell lines largely depends on up-regulation of
clusterin/apolipo-protein J. Int J Cancer. 120:611–622. 2007.
View Article : Google Scholar
|
|
46
|
Zhang H, Kim JK, Edwards CA, Xu Z,
Taichman R and Wang CY: Clusterin inhibits apoptosis by interacting
with activated Bax. Nat Cell Biol. 7:909–915. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yasukawa T, Tokunaga E, Ota H, Sugita H,
Martyn JA and Kaneki M: S-nitrosylation-dependent inactivation of
Akt/protein kinase B in insulin resistance. J Biol Chem.
280:7511–7518. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhang B, Shimada Y, Kuroyanagi J,
Nishimura Y, Umemoto N, Nomoto T, Shintou T, Miyazaki T and Tanaka
T: Zebrafish xenotransplantation model for cancer stem-like cell
study and high-throughput screening of inhibitors. Tumour Biol.
35:11861–11869. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kelleher ZT, Potts EN, Brahmajothi MV,
Foster MW, Auten RL, Foster WM and Marshall HE: NOS2 regulation of
LPS-induced airway inflammation via S-nitrosylation of NF-{kappa}B
p65. Am J Physiol Lung Cell Mol Physiol. 301:L327–L333. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Marshall HE and Stamler JS: Inhibition of
NF-kappa B by S-nitrosylation. Biochemistry. 40:1688–1693. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Wilson MR and Zoubeidi A: Clusterin as a
therapeutic target. Expert Opin Ther Targets. 21:201–213. 2017.
View Article : Google Scholar
|
|
52
|
Chun YJ: Knockdown of clusterin expression
increases the in vitro sensitivity of human prostate cancer cells
to paclitaxel. J Toxicol Environ Health A. 77:1443–1450. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
García-Aranda M, Téllez T, Muñoz M and
Redondo M: Clusterin inhibition mediates sensitivity to
chemotherapy and radiotherapy in human cancer. Anticancer Drugs.
28:702–716. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Trougakos IP, So A, Jansen B, Gleave ME
and Gonos ES: Silencing expression of the clusterin/apolipoprotein
j gene in human cancer cells using small interfering RNA induces
spontaneous apoptosis, reduced growth ability, and cell
sensitization to genotoxic and oxidative stress. Cancer Res.
64:1834–1842. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Al Nakouzi N, Wang CK, Beraldi E, Jager W,
Ettinger S, Fazli L, Nappi L, Bishop J, Zhang F, Chauchereau A, et
al: Clusterin knockdown sensitizes prostate cancer cells to taxane
by modulating mitosis. EMBO Mol Med. 8:761–778. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Beer TM, Hotte SJ, Saad F, Alekseev B,
Matveev V, Fléchon A, Gravis G, Joly F, Chi KN, Malik Z, et al:
Custirsen (OGX-011) combined with cabazitaxel and prednisone versus
cabazitaxel and prednisone alone in patients with metastatic
castration-resistant prostate cancer previously treated with
docetaxel (AFFINITY): A randomised, open-label, international,
phase 3 trial. Lancet Oncol. 18:1532–1542. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Chi KN, Higano CS, Blumenstein B, Ferrero
JM, Reeves J, Feyerabend S, Gravis G, Merseburger AS, Stenzl A,
Bergman AM, et al: Custirsen in combination with docetaxel and
prednisone for patients with metastatic castration-resistant
prostate cancer (SYNERGY trial): A phase 3, multicentre,
open-label, randomised trial. Lancet Oncol. 18:473–485. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Kim N, Yoo JC, Han JY, Hwang EM, Kim YS,
Jeong EY, Sun CH, Yi GS, Roh GS, Kim HJ, et al: Human nuclear
clusterin mediates apoptosis by interacting with Bcl-XL through
C-terminal coiled coil domain. J Cell Physiol. 227:1157–1167. 2012.
View Article : Google Scholar
|
|
59
|
Peix L, Evans IC, Pearce DR, Simpson JK,
Maher TM and McAnulty RJ: Diverse functions of clusterin promote
and protect against the development of pulmonary fibrosis. Sci Rep.
8:19062018. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Bhutia SK, Das SK, Kegelman TP, Azab B,
Dash R, Su ZZ, Wang XY, Rizzi F, Bettuzzi S, Lee SG, et al:
mda-7/IL-24 differentially regulates soluble and nuclear clusterin
in prostate cancer. J Cell Physiol. 227:1805–1813. 2012. View Article : Google Scholar
|
|
61
|
Siemens DR, Heaton JP, Adams MA, Kawakami
J and Graham CH: Phase II study of nitric oxide donor for men with
increasing prostate-specific antigen level after surgery or
radiotherapy for prostate cancer. Urology. 74:878–883. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Cajigas-Du Ross CK, Martinez SR,
Woods-Burnham L, Durán AM, Roy S, Basu A, Ramirez JA,
Ortiz-Hernández GL, Ríos-Colón L, Chirshev E, et al: RNA sequencing
reveals upreg-ulation of a transcriptomic program associated with
stemness in metastatic prostate cancer cells selected for taxane
resistance. Oncotarget. 9:30363–30384. 2018.PubMed/NCBI
|
|
63
|
Plenchette S, Romagny S, Laurens V and
Bettaieb A: NO and cancer: Itinerary of a double agent. Med Sci
(Paris). 32:625–633. 2016.In French. View Article : Google Scholar
|
